These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24466321)

  • 1. Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models.
    Jiang C; Niu J; Li M; Teng Y; Wang H; Zhang Y
    PLoS One; 2014; 9(1):e87036. PubMed ID: 24466321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, purification, and characterization of a neovasculature targeted rmhTNF-alpha in Escherichia coli.
    Wang H; Yan Z; Shi J; Han W; Zhang Y
    Protein Expr Purif; 2006 Jan; 45(1):60-5. PubMed ID: 16027006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.
    Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X
    Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter, randomized, double-blind study of recombinant mutated human tumor necrosis factor-α in combination with chemotherapies in cancer patients.
    Li M; Xu T; Zhang Z; Xue X; Zhang C; Qin X; Li W; Hao Q; Zhang W; Zhang Y
    Cancer Sci; 2012 Feb; 103(2):288-95. PubMed ID: 22085427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
    Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
    Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity.
    Li M; Qin X; Xue X; Zhang C; Yan Z; Han W; Komarck C; Wang TD; Zhang Y
    Anticancer Drugs; 2010 Mar; 21(3):243-51. PubMed ID: 20166241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model.
    Kim YI; Kim KW; Lee HK; Park J; Chung JW; Youn H; Kim SJ; Kim DH; Tseng JC; Lee JM
    Anticancer Res; 2014 Apr; 34(4):1715-22. PubMed ID: 24692701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
    Cao L; Du P; Jiang SH; Jin GH; Huang QL; Hua ZC
    Mol Cancer Ther; 2008 Apr; 7(4):851-61. PubMed ID: 18413798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin.
    Ji W; Yuan M; Zhang L; Zhang H; Jiao J; Gao Z
    Mol Med Rep; 2017 Jun; 15(6):3865-3870. PubMed ID: 28393225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rmhTNF-α combined with cisplatin inhibits proliferation of A549 cell line in vitro.
    Xia LM; Zhou YY
    Chin Med Sci J; 2014 Sep; 29(3):185-7. PubMed ID: 25264888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.
    Ten Hagen TL; Van Der Veen AH; Nooijen PT; Van Tiel ST; Seynhaeve AL; Eggermont AM
    Int J Cancer; 2000 Sep; 87(6):829-37. PubMed ID: 10956394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.
    Hira SK; Mondal I; Bhattacharya D; Gupta KK; Manna PP
    Int J Biochem Cell Biol; 2015 Oct; 67():1-13. PubMed ID: 26255115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells serve as a "Trojan horse" for oncolytic adenovirus delivery in the treatment of mouse prostate cancer.
    Li ZL; Liang X; Li HC; Wang ZM; Chong T
    Acta Pharmacol Sin; 2016 Aug; 37(8):1121-8. PubMed ID: 27345628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
    Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
    Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
    Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
    Zhu F; Jiang Y; Luo F; Li P
    J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of recombinant human TNF in human cancer therapy.
    Lejeune FJ; Liénard D; Matter M; Rüegg C
    Cancer Immun; 2006 Mar; 6():6. PubMed ID: 16551058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse model.
    Wang D; Fu J; Shi Y; Peng D; Yuan L; He B; Dai W; Zhang H; Wang X; Tian J; Zhang Q
    J Control Release; 2016 Sep; 238():186-196. PubMed ID: 27422610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.